Skip to content Skip to navigation

process development

How Can a Closed CAR-T Manufacturing Process De-Risk Your Process, Reduce Costs and Improve Efficiency?

In a previous post we introduced chimeric antigen receptor T-cell (CAR-T) therapy - a new form of cancer therapy based on genetically reprogramming the body’s immune system that has been described as a “breakthrough” and “revolutionary” by the medical and scientific communities.

This post will explore how developing customized solutions for system closure can solve a key technical bottleneck and advance CAR-T manufacturing.


Subscribe to RSS - process development